



Life Sciences

2009-2010: Life sciences leaders turn to WilmerHale for legal advice and business advantage.

We provide incisive solutions to the business challenges facing biotechnology, pharmaceutical and medical device companies at all stages of growth. For over four decades, we have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

Counsel of Choice to Life Sciences Leaders...from Biotech to Medical Devices

Mergers and Acquisitions

 <i>Acquisition by Takeda Pharmaceutical</i> \$8,800,000,000 May 2008	 <i>Acquisition of Targanta Therapeutics</i> \$137,000,000 February 2009	 <i>Acquisition by Dainippon Sumitomo Pharma</i> \$2,600,000,000 October 2009	 <i>Acquisition by Covidien</i> \$210,000,000 November 2009
 <i>Acquisition of Signature Genomic Laboratories</i> \$90,000,000 Pending*	 <i>Acquisition by Celldex Therapeutics</i> \$94,500,000 October 2009	 <i>Acquisition by Celgene</i> \$640,000,000 (including milestone payments) January 2010	

Public Offerings and Rule 144A Placements

 <i>Rule 144A Placements of Senior Notes due 2012 and 2014</i> \$750,000,000 Counsel to Issuer November 2009	 <i>Public Offerings of Common Stock</i> \$96,719,000 Counsel to Issuer April and October 2009	 <i>Initial Public Offering of Common Stock</i> \$89,717,000 Counsel to Issuer March 2010	 <i>Public Offering of Common Stock</i> \$49,450,000 Counsel to Issuer September 2009
 <i>Public Offering of Common Stock</i> \$45,517,000 Counsel to Placement Agent February 2009	 <i>Public Offering of Common Stock</i> \$44,550,000 Counsel to Underwriters October 2009	 <i>Public Offering of Common Stock</i> \$48,750,000 Counsel to Underwriters November 2009	

Strategic Alliances and Collaborations

 <i>Collaboration with Cubist to develop novel ion channel pain drugs</i>	 <i>Drug development and commercialization agreements</i>	 <i>Worldwide license of HIV treatment to GSK</i>	 <i>Drug development collaborations with Novartis and Eli Lilly</i>	 <i>Collaboration with Sanofi-Aventis for oncology antibody drugs</i>
 <i>Research and exclusive license agreement with Teva</i>	 <i>Collaboration with Seattle Genetics for oncology antibody drugs</i>	 <i>Collaboration with GSK for the development of novel deuterium-modified drugs</i>	 <i>Collaboration with Sanofi-Aventis for Wellstat's oral insulin sensitizer for type 2 diabetes</i>	

Venture Capital Financings

 \$40,000,000 <i>Fourth Round</i> May 2009	 \$88,000,000 <i>Late Stage</i> May and October 2009	 \$26,000,000 <i>First Round</i> October 2009	 \$47,750,000 <i>First Round</i> October 2009	 \$30,000,000 <i>Second Round</i> December 2009
 \$70,000,000 <i>Late Stage</i> November 2009	 \$35,000,000 <i>Second Round</i> January 2010	 \$22,000,000 <i>Third Round</i> May 2009	 \$40,000,000 <i>First Round</i> April 2010	

*As of April 30, 2010



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

WilmerHale recognizes its corporate responsibility to environmental stewardship.



wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers regulated by the Solicitors Regulation Authority (SRA No. 287488). In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. This material is for general informational purposes only and does not represent our legal advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all relevant legal developments. Prior results do not guarantee a similar outcome. © 2010 Wilmer Cutler Pickering Hale and Dorr LLP